Isoyama S, Ishikawa N, Hamai K, et al.

COPD, chronic obstructive pulmonary disease
CRSwNP, chronic rhinosinusitis with nasal polyps
EGPA, eosinophilic granulomatosis with polyangiitis
FEV₁, forced expiratory volume in 1 second
FF, fluticasone furoate
HES, hypereosinophilic syndrome
ICS, inhaled corticosteroid
IL, interleukin
LABA, long acting β-agonist
LAMA, long acting muscarinic antagonist
NIAID, National Institute of Allergy and Infectious Diseases
NIH, National Institute of Health
R/R, relapse-remitting or refractory
RWE, real-world evidence
SABA, short-acting β-agonist
UMEC, umeclidinium
VI, vilanterol

Includes three categories, investigator-initiated studies, supportive collaborative studies and GSK-sponsored studies. Investigator-initiated studies were initiated, developed, designed and conducted by external investigators who assumed sole responsibility for the study, and GSK’s only involvement was financial support via an independent grant. Supportive collaborative studies were conducted by external investigators who assumed sole responsibility for the study but involved greater collaboration with GSK, for aspects of study design, data interpretation or provision of study-specific product (± matching placebo) free of charge. GSK-sponsored studies are those in which GSK were fully responsible for the design, initiation and funding of the study.

Clinical study was initiated, developed, designed and conducted by external investigators who assumed sole responsibility for the study.

Clinical study was supported financially or sponsored by a non-GSK pharmaceutical company.